Pulmonx Corp (LUNG) - Total Assets
Based on the latest financial reports, Pulmonx Corp (LUNG) holds total assets worth $114.73 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pulmonx Corp - Total Assets Trend (2013–2025)
This chart illustrates how Pulmonx Corp's total assets have evolved over time, based on quarterly financial data. Also see how much is Pulmonx Corp worth for the company's overall valuation and market capitalisation.
Pulmonx Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Pulmonx Corp's total assets of $114.73 Million consist of 78.7% current assets and 21.4% non-current assets. Review Pulmonx Corp balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.2% |
| Accounts Receivable | $12.07 Million | 9.3% |
| Inventory | $15.85 Million | 12.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $700.00K | 0.5% |
| Goodwill | $2.33 Million | 1.8% |
Asset Composition Trend (2013–2025)
This chart illustrates how Pulmonx Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Pulmonx Corp (LUNG) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pulmonx Corp's current assets represent 78.7% of total assets in 2025, a decrease from 94.0% in 2013.
- Cash Position: Cash and equivalents constituted 54.2% of total assets in 2025, down from 82.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 12.3% of total assets.
Pulmonx Corp Competitors by Total Assets
Key competitors of Pulmonx Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Pulmonx Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.32 | 5.35 | 10.25 |
| Quick Ratio | 3.52 | 4.63 | 9.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $67.73 Million | $97.57 Million | $205.43 Million |
Pulmonx Corp - Advanced Valuation Insights
This section examines the relationship between Pulmonx Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | -20.6% |
| Total Assets | $129.29 Million |
| Market Capitalization | $85.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pulmonx Corp's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pulmonx Corp's assets decreased by 20.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pulmonx Corp (2013–2025)
The table below shows the annual total assets of Pulmonx Corp from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $129.29 Million | -20.61% |
| 2024-12-31 | $162.85 Million | -8.40% |
| 2023-12-31 | $177.78 Million | -8.21% |
| 2022-12-31 | $193.68 Million | -17.65% |
| 2021-12-31 | $235.17 Million | -10.82% |
| 2020-12-31 | $263.71 Million | +392.61% |
| 2019-12-31 | $53.53 Million | +256.58% |
| 2018-12-31 | $15.01 Million | +924.73% |
| 2017-12-31 | $1.47 Million | +153.49% |
| 2016-12-31 | $577.97K | -42.54% |
| 2015-12-31 | $1.01 Million | +112.31% |
| 2014-12-31 | $473.73K | +351.20% |
| 2013-12-31 | $104.99K | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more